Unmet Needs and Emerging Therapies in HS


Andrew Baker PA-C, MBA, reviews unmet needs for the clinical management of moderate-to-severe HS and shares insight on novel and emerging therapies in the pipeline.

Andrew Baker, MBA, PA-C: A multidisciplinary approach is needed for clinical management. Many clinicians are not on the same page about this disease or the treatment, so if you’re working with other specialists, there is a knowledge gap or an educational gap on this disease and how to effectively treat it. And that spills over to the patient, and they’re getting conflicting answers from different clinicians. And it can be very upsetting to the patient, and it can deter them from seeking treatment. So there is a real need for a call to action across all specialties. Also, given the somewhat limited improvements for some of these patients on TNF-⍺ [tumor necrosis factor-⍺] therapy, there is definitely a need for novel systemic treatment as well.

The formation of the inflammatory nodules, abscesses, and sinus tracts and fistulas is characterized by this large influx of key proinflammatory mediators, such as TNF-⍺, IL-1, IL-17, IL-12, and IL-23. And now some of these new therapies are looking to target some of these other inflammatory mediators to try to stop the disease progression. A good example is IL-17.

The upcoming expected approval of secukinumab is definitely on a lot of our minds at this time. This medicine has been used frequently off-label for patients with HS [hidradenitis suppurativa] or patients who have a concomitant HS with psoriasis. And there’s been a lot of benefit to those patients. And the reason we think this medicine is going to work is that it does bind and interferes with the IL-17 cytokine, which has been known to reduce inflammation, and alters the immune response of this cascade.

Transcript Edited for Clarity

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
Secukinumab and Bimekizumab for Hidradenitis Suppurativa
© 2024 MJH Life Sciences

All rights reserved.